Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro

Yang,Yanhong; Zhou,Wenwen; Wu,Jiandong; Yao,Lixin; Xue,Lei; Zhang,Qianyi; Wang,Zhenzhen; Wang,Xiaoyu; Dong,Shu; Zhao,Jiangman; Yin,Duanduan

doi:10.3892/ol.2018.7923

Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro

Authors:
- Yanhong Yang
- Wenwen Zhou
- Jiandong Wu
- Lixin Yao
- Lei Xue
- Qianyi Zhang
- Zhenzhen Wang
- Xiaoyu Wang
- Shu Dong
- Jiangman Zhao
- Duanduan Yin
View Affiliations

Affiliations: Department of Oncology, Qinhuangdao No. 1 People's Hospital, Qinhuangdao, Hebei 066000, P.R. China, College of Pharmacy, University of Tasmania, Hobart, TAS 7001, Australia, Postgraduate College of Chengde Medical University, Chengde, Hebei 067000, P.R. China, Biotecan Medical Diagnostics Co., Ltd., Shanghai 201203, P.R. China
Published online on: February 1, 2018 https://doi.org/10.3892/ol.2018.7923
Pages: 5280-5284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nimotuzumab, a humanized IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR), increases radiosensitivity in lung cancer. Cisplatin is an effective antitumor agent in lung cancer. In the present study, the antitumor activity of nimotuzumab combined with cisplatin was investigated in A549 lung cancer cells. Viability, cell cycle distribution and cyclin D1 expression were assessed following treatment with nimotuzumab alone, cisplatin alone, nimotuzumab in combination with cisplatin, and nimotuzumab followed sequentially by cisplatin. The inhibitory effect on cell viability of nimotuzumab sequentially followed by cisplatin was higher compared with cisplatin alone (82.17±1.62 vs. 56.97±1.42%). Compared with treatment by cisplatin alone, cell cycle analysis by flow cytometry demonstrated that the percentage of cells in the G0/G1 phase was increased when A549 cells were treated with nimotuzumab followed sequentially by cisplatin (P<0.01). However, the proportion of cells in G0/G1 phase was decreased when A549 cells were treated with nimotuzumab and cisplatin simultaneously compared with cisplatin alone (P<0.05). Cyclin D1 expression was decreased in all chemotherapy treatment groups; the most significant decrease was in A549 cells treated with nimotuzumab followed sequentially by cisplatin. Nimotuzumab may enhance the antitumor activity of cisplatin on A549 cells. The cell cycle arrest at G0/G1 observed may have been due to decreased cyclin D1 levels. Potential antagonism was identified when A549 cells were treated with nimotuzumab and cisplatin simultaneously, indicating that targeted therapy may be more effective when administered prior to conventional chemotherapy.

View Figures

View References

1	Provencio M, Isla D, Sánchez A and Cantos B: Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. J Thorac Dis. 3:197–204. 2011.PubMed/NCBI
2	Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in China, 2003–2005: A population-based study. Int J Cancer. 136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
3	Non-Small Cell Lung Cancer Treatment (PDQ^®): National Cancer Institute (US). 2013, https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
4	Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol. 22:777–784. 2004. View Article : Google Scholar
5	Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR and Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2053–2063. 2000.
6	Crombet T, Torres L, Neninger E, Catalá M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Pérez R and Lage A: Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 26:139–148. 2003. View Article : Google Scholar
7	Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and Giaccone G: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 29:2121–2127. 2011. View Article : Google Scholar
8	Stella GM, Scabini R, Inghilleri S, Cemmi F, Corso S, Pozzi E, Morbini P, Valentini A, Dore R, Ferrari S, et al: EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol. 139:1327–1335. 2013. View Article : Google Scholar
9	Raben D, Helfrich B and Bunn PA Jr: Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 59 Suppl 2:S27–S38. 2004. View Article : Google Scholar
10	Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 97:643–655. 2005. View Article : Google Scholar
11	Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar
12	Yoshida T, Zhang G and Haura EB: Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer. Biochem Pharmacol. 80:613–623. 2010. View Article : Google Scholar
13	Xu N, Fang W, Mu L, Tang Y, Gao L, Ren S, Cao D, Zhou L, Zhang A, Liu D, et al: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget. 7:3884–3896. 2016.
14	Sabattini S, Mancini FR, Marconato L, Bacci B, Rossi F, Vignoli M and Bettini G: EGFR overexpression in canine primary lung cancer: Pathogenetic implications and impact on survival. Vet Comp Oncol. 12:237–248. 2014. View Article : Google Scholar
15	Tebbutt N, Pedersen MW and Johns TG: Targeting the ERBB family in cancer: Couples therapy. Nat Rev Cancer. 13:663–673. 2013. View Article : Google Scholar
16	Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R and Brade A: Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol. 67:837–845. 2011. View Article : Google Scholar
17	Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, et al: Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study. Clin Cancer Res. 16:2474–2482. 2010. View Article : Google Scholar
18	Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, et al: Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 22:1646–1654. 2004. View Article : Google Scholar
19	Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, et al: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biol Ther. 5:375–379. 2006. View Article : Google Scholar
20	Ma NY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, Zhang YW, et al: Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus. Int J Clin Oncol. 19:297–302. 2014. View Article : Google Scholar
21	Herbst RS and Bunn PA Jr: Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 9:5813–5824. 2003.
22	Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK and Bunn PA Jr: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 11:795–805. 2005.
23	Cascone T, Morelli MP and Ciardiello F: Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann Oncol. 17 Suppl 2:ii46–ii48. 2006. View Article : Google Scholar
24	Babu KG, Prabhash K, Vaid AK, Sirohi B, Diwakar RB, Rao R, Kar M, Malhotra H, Nag S, Goswami C, et al: Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: A multicenter, randomized, open-label Phase II study. Onco Targets Ther. 7:1051–1060. 2014. View Article : Google Scholar
25	Diaz Miqueli A, Blanco R, Garcia B, Badia T, Batista AE, Alonso R and Montero E: Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt). 26:423–431. 2007. View Article : Google Scholar
26	Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K and Nakagawa K: Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer. 98:749–755. 2008. View Article : Google Scholar
27	Maioli E, Torricelli C, Fortino V, Carlucci F, Tommassini V and Pacini A: Critical appraisal of the MTT assay in the presence of rottlerin and uncouplers. Biol Proced Online. 11:227–240. 2009. View Article : Google Scholar
28	Vindeløv LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 3:323–327. 1983. View Article : Google Scholar
29	Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: Past and present. Expert Opin Investig Drugs. 23:295–304. 2014. View Article : Google Scholar
30	Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H and Arvind AS: Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 1:41–48. 2009. View Article : Google Scholar
31	Massimino M, Bode U, Biassoni V and Fleischhack G: Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther. 11:247–256. 2011. View Article : Google Scholar
32	Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YÁ, Moreno BP, Alvarez ES, et al: Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 13:600–605. 2012. View Article : Google Scholar
33	Wang Y, Pan L, Sheng XF, Chen S and Dai JZ: Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Asia Pac J Clin Oncol. 12:e23–e29. 2016. View Article : Google Scholar
34	Zhao KL, Hu XC, Wu XH, Fu XL, Fan M and Jiang GL: A phase I dose escalation study of nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. Invest New Drugs. 30:1585–1590. 2012. View Article : Google Scholar
35	Ji YH, Yang XY, Wu JQ, Huo XQ, Li WW, Li GJ, Mu YL and Lu P: Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. Eur Rev Med Pharmacol Sci. 19:586–591. 2015.
36	Du F, Zheng Z, Shi S, Jiang Z, Qu T, Yuan X, Sun Y, Song Y, Yang L, Zhao J, et al: S-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer: A randomized, open-label phase 2 trial. Medicine (Baltimore). 94:e9582015. View Article : Google Scholar